biz.yahoo.com
Ugh. Molecules are dropping like flies. Now, the question is.... at
this market cap, does this modest evidence for proof of principle mean
that we're not headed too far south on Monday morning? I'll be
working on valuation for much of the weekend. Why do they keep saying "oral"??........
<TABLE>
Summary of Certain Drug Discovery Programs
- ------------------------------------------------------------------------------------------------------------
Collaborative
Program(1) Receptor(s) Primary Indication(s) Status(2) Partner Licensee
- ------------------------------------------------------------------------------------------------------------
Serotonin 1F Acute Migraine Early Preclinical(3) Eli Lilly
__(4) Depression Phase I Clinical Eli Lilly
__(4)(5) Depression Late Preclinical Eli Lilly
__(4)(5) Depression Late Preclinical Eli Lilly
1A Smoking Cessation Late Preclinical(6) Eli Lilly
2C Obesity Early Preclinical Eli Lilly
Alpha
Adrenergic 1a Benign Prostatic
Hyperplasia Phase II Clinical Merck
2a, 2b or 2c(4) Pain Leads Identified Grunenthal
1a, 1b or 1d (7) (7) Glaxo
Neuropeptide Y Y5 Obesity Early Preclinical Novartis
Y2 Pain Discovery (8)
Galanin 1, 2, and 3 Obesity, Diabetes, Leads Identified Warner-
Alzheimer's Disease, Lambert
Depression and Pain
</TABLE>
(snip)
(3) In August 1998, the Company and Lilly announced that LY334370, a
selective serotonin 1F receptor agonist (SSOFRA), would advance to the
Phase III Clinical stage. The Phase III Clinical trials were scheduled
to commence in March 1999. However, in March, Lilly informed the
Company that it was discontinuing commercial development of LY334370 as
a result of its recent review of data from an animal toxicology study.
Lilly continues to maintain that all data to date continue to support
the hypothesis that SSOFRAs represent a new class of compounds that may
effectively treat migraine pain via neuronal mechanisms without the
cardiovascular side effects associated with products currently on the
market, and has informed the Company that it will continue its efforts
to develop alternative SSOFRAs with an improved safety profile.
(4) The specific receptor subtype that is the focus of this program is
confidential to the Company and its collaborative partner or other
licensee.
(5) The serotonin receptor subtype which is the target of this program is
different from the serotonin receptor subtype which is the target of
the depression program that is in the Phase I Clinical stage and is
different from the serotonin receptor subtype which is the target of
the other depression program that is in the Late Preclinical stage.
Accordingly, the compound which is the focus of this depression program
is not a back-up to the compound which is the focus of the depression
program that is in the Phase I Clinical stage or which is the focus of
the other depression program that is in the Late Preclinical stage.
(6) During the third quarter of 1998, Lilly informed the Company that it
would not continue to develop this compound but would instead seek a
development partner or licensee for the compound that is the focus of
this program.
(7) The therapeutic indications that are the focus of Glaxo's program and
the status of such program are not known by the Company.
(8) While Synaptic is currently conducting this program independently,
Synaptic has agreed to reserve the Y2 receptor as a potential target
for drugs for the alleviation of pain exclusively for its collaboration
with Grunenthal. |
